Xcellent idea
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 26 February, 2002 - 21:00
LOCAL medical devices company Xcell Diagnostics has formalised its acquisition of local business InfaMed and the patented Funhaler.
InfaMed has developed a small volume spacer device for children who suffer from asthma, named the Funhaler.
The fully-approved acquisition of shares in InfaMed, announced at this week’s general meeting, makes it a wholly owned subsidiary of Xcell, according to managing director Barry Fehlberg.
Clinical trials of the Funhaler are currently under way at the University of Western Australia with the support of a $450,000 Federal Government grant.
Xcell is also involved in research on a skin cancer analysis, which involves funding skin cancer research utilising diffuse reflectance spectroscopy at the UWA.
Companies: